TG Therapeutics, Inc.

TG Therapeutics, Inc.

生物技术研究

New York,NY 27,097 位关注者

TG is a biopharmaceutical company focused on the development of novel treatments for B-cell diseases.

关于我们

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).

网站
https://www.tgtherapeutics.com/
所属行业
生物技术研究
规模
201-500 人
总部
New York,NY
类型
上市公司
创立
2011
领域
Biotechnology、hematological malignancies、non-Hodgkin's lymphoma、multiple sclerosis、b-cell diseases、ublituximab和umbralisib

地点

TG Therapeutics, Inc.员工

动态

相似主页

查看职位

融资